Sulindac-induced Cholestatic Hepatitis and Acute Pancreatitis in a Patient having Systemic Sclerosis with Anti-RNP Antibody: report of a case.
- Author:
Hyun Kyu CHANG
1
;
Yeon Suk KIM
;
Hoon JEONG
;
Sung Oh PARK
;
Su Hee KIM
;
Hyuk KO
;
Gil Hyun KANG
;
Jeong Uk KIM
Author Information
1. Department of Internal Medicine, Asan-foundation Kangnung Hospital, Kangnung, Korea.
- Publication Type:Original Article
- Keywords:
Sulindac;
Cholestatic hepatitis;
Pancreatitis;
Systemic sclerosis;
Mixed connective tissue disease
- MeSH:
Adult;
Anti-Inflammatory Agents, Non-Steroidal;
Classification;
Female;
Hepatitis*;
Humans;
Liver Function Tests;
Mixed Connective Tissue Disease;
Pancreatitis*;
Scleroderma, Systemic*;
Sulindac
- From:The Journal of the Korean Rheumatism Association
2000;7(2):185-189
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Sulindac is a commonly used nonsteroidal anti-inflammatory drug (NSAID). It is relatively economical and seems to be less nephrotoxic due to its property of minimal renal prostaglandin inhibition. Although hepatic injury has been infrequently reported for nearly all NSAIDs currently on the market, sulindac has more commonly been associated with hepatotoxicity. In addition, it has been known that sulindac is the agent to have a definite association with pancreatitis. We describe a 37-year-old woman who developed cholestatic hepatitis and acute pancreatitis in association with sulindac. This patient met the diagnostic criteria of both mixed connective tissue disease and systemic sclerosis, in which the disease classification needs to be clarified. While being treated with sulindac, close observation and periodic liver function test seem to play an important role.
